154P Neoadjuvant chemotherapy plus tislelizumab followed by adjuvant tislelizumab for locoregionally advanced nasopharyngeal carcinoma (NPC): A single-arm, phase II trial. (December 2022) - Sun, S.; Huang, X.; Wang, K.; Wu, R.; Wang, J.; Y. Zhang; Zhang, J.; Chen, X.; Qu, Y.; Luo, J.; J. Yi; Zhou, S.